Bavarian Nordic CEO Anders Hedegaard Elected as Co-Chair of the Alliance for Biosecurity
WASHINGTON, DC - July 1, 2013 - Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that the Alliance for BioSecurity has elected Anders Hedegaard, President and CEO, Bavarian Nordic, and Elizabeth Posillico, PhD, President and CEO, Elusys as its new co-chairs. They will represent the Alliance before the U.S. government and other agencies, to advance the development of new medical countermeasures to be used against Chemical, Biological, Radiological and Nuclear threats. Hedegaard and Posillico will each serve a two-year term, which commenced on June 1, 2013.
The Alliance for Biosecurity was formed in 2005 with the vision of improving the U.S. biosecurity through the development of medical countermeasures (MCMs) to address a range of bioterrorism and natural pandemic threats. Activities of the Alliance include educating Congress and other government stakeholders about biosecurity and drug development issues, promoting the success of the Biomedical Advanced Research and Development Authority (BARDA), advancing the science of animal model development, accelerating MCM development and presenting consensus policy proposals to the government.
The Alliance has successfully advocated for preserving the BioShield Special Reserve Fund and BARDA to maintain funding for the development and procurement of MCMs. In addition, several Alliance recommendations for enhancing the regulatory pathway for MCMs and better integrating the Food and Drug Administration into the development process were adopted in recently enacted legislation.
"Alliance members applaud the recent five-year reauthorization of the Pandemic and All-Hazards Preparedness Act, which extends funding for Project BioShield and also enacts initiatives to speed the development of medical countermeasures," said Hedegaard. "We look forward to working with elected officials to safeguard public health by ensuring that important vaccines and therapeutics against life-threatening infectious diseases continue to be developed, supplied and are available when needed."